Potter Anderson Helps Secure Appellate Victory for Gilead Sciences

December 12, 2017
Firm News

Delaware’s Supreme Court affirmed a March 2017 Court of Chancery ruling which held that Gilead Sciences, Inc., one of the world’s largest biopharmaceutical companies, was not required to make a $50 million milestone payment to the former stockholders of Calistoga Pharmaceuticals, a company Gilead acquired in 2011.

At issue was whether the limited European Union approval received by Gilead for a blood cancer drug developed by Calistoga prior to its acquisition met the threshold of “disease level” approval required to trigger a milestone payment under the terms of the merger agreement governing the acquisition.

Serving as Delaware counsel to Gilead in collaboration with Irell & Manella, partner Brian Ralston led Potter Anderson’s representation with associate Aaron Sims. Ralston and Sims represented Gilead in both the appeal and the underlying case in the Court of Chancery.

News of the decision was reported by Law360.

Related Professionals

Related Capabilities

Media Contact

Lisa Altman, Jaffe PR, Senior Vice President

About Potter Anderson

Potter Anderson & Corroon LLP is one of the largest and most highly regarded Delaware law firms, providing legal services to regional, national, and international clients. With more than 100 attorneys, the firm’s practice is centered on corporate law, corporate litigation, intellectual property, commercial litigation, bankruptcy, labor and employment, and real estate.

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.